Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment

Journal of Dermatological Treatment

Volumn 21, Issue 5, 2010, Pages 267-271

  Kaur, Ravneet R ^a   Alikhan, Ali ^b   Maibach, Howard I ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Actinic keratosis; Carac ; Efudex ; Topical 5 fluorouracil; Topical 5 FU

Indexed keywords

FLUOROURACIL;

ACTINIC KERATOSIS; APPLICATION SITE EDEMA; APPLICATION SITE REACTION; CONJUNCTIVITIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRY SKIN; EROSION; ERYTHEMA; EYE IRRITATION; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN IRRITATION; SKIN PAIN; SKIN PIGMENTATION; SKIN PRURITUS; SKIN REDNESS;

ADMINISTRATION, CUTANEOUS; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; FACIAL DERMATOSES; FLUOROURACIL; HUMANS; KERATOSIS, ACTINIC; OINTMENTS; SCALP DERMATOSES; TREATMENT OUTCOME;

EID: 77955440071     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903341937     Document Type: Review

References (28)

1. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4-7.
2. Heaphy MR Jr, Ackerman AB. The nature of solar keratosis: A critical review in historical perspective. J Am Acad Dermatol. 2000;43:138-150.
3. Rowert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, et al. Actinic keratosis is an early in situ squamous cell carcinoma: A proposal for reclassification. Br J Dermatol. 2007; (156 suppl 3):8-12.
4. Lawrence N. New and emerging treatments for photoaging. Dermatol Clin. 2000;18:99-112.
5. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000;42:25-28.
6. Gupta AK, Davey V, McPhail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005;9:209-214.
7. Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol. 1982;7:631-632.
8. Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freemen RG. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg. 1997;23:191-196.
9. Drake LA, Ceilley RI, Cornelison RL, Dobes WL, Dorner W, Goltz RW, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol. 1995;32:95-98.
10. Feldman SR, Fleischer AB Jr, Williford PM, Jorizzo JL. Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol. 1999;40:43-47.
11. Williams HC. Actinic keratoses and Bowen's disease In: Williams HC, editor. Evidence based dermatology. 2nd ed. Malden, MA: Blackwell Publishing; 2008. p. 301-302.
12. Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: A randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140:813-816.
13. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluoro- uracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990-1000.
14. Weiss J, Menter A, Hevia O, Jones T, Ling M, Rist T, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002;70:22-29.
15. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: A double-blind, vehicle-controlled, long- term study. J Drugs Dermatol. 2006;5:133-139.
16. Jorizzo J, Stewart D, Bucko A, Davis SA, Espy P, Hino P, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002;70:335-339.
17. Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic kera- toses. J Drugs Dermatol. 2003;2:629-635.
18. Dillaha CJ, Jansen GT, Honeycutt WM, Holt GA. Further studies with topical 5-fluorouracil. Arch Dermatol. 1965;92:410-417.
19. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immu- nocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;(157 suppl 2):34-40.
20. Shuttleworth D, Marks R. A comparison of the effects of intralesional interferon alpha-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease. J Dermatolog Treat. 1989;1:65-68.
21. Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther. 2001;23:901-907.
22. Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther. 2001;23:908-920.
23. Weinstock MA, Bingham SF, Cole GW, Eilers D, Naylor MF, Kalivas J, et al. Reliability of counting actinic keratoses before and after brief consensus discussion: The VA topical tretinoin chemoprevention (VATTC) trial. Arch Dermatol. 2001;137:1055-1058.
24. Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluoro- uracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131:176-181.
25. Breza T, Taylor R, Eaglstein WH. Noninflammatory destruction of actinic keratoses by fluorouracil. Arch Dermatol. 1976;112:1256-1258.
26. Ostertag JU, Quaedvlieg PJ, van der Geer S, Nelemans P, Christianen ME, Neumann MH, et al. A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med. 2006;38:731-739.
27. PDR guide to drug interactions, side effects, indications. Montvale, NJ: Thomson PDR;2006. p. v
28. Habif TP. Clinical dermatology: A color guide to diagnosis and therapy. Philadelphia: Mosby; 2004.